1
|
Pinnaro P, Takanen S, Landoni V, Vici P, Nucciarelli S, Botti C, Sanguineti G. Ten Fraction Adjuvant Hypofractionated Radiotherapy in Node Positive Breast Cancer: 3 Year-Follow-Up of a Phase II Toxicity Study. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.778] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
2
|
Modini C, Albertucci M, Cicconetti F, Tirindelli Danesi D, Cristiani R, Botti C, Pasquali Lasagni R, Stipa S. A New Multiparametric Classification in Lung Cancer Patients - S.M.I.G. Tumori 2018; 69:437-43. [PMID: 6316599 DOI: 10.1177/030089168306900511] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The classification of bronchogenic carcinoma as a function of the prognosis is still an open field. The evaluation of stage, by use of the TNM system, and histologic cell type is not sufficient to guarantee a correct prognosis. The growth rate of the neoplasm is another important parameter. We propose a classification that takes into account the stage (S), histologic cell type (M), immune status (I) and the growth rate of the primary tumor (G): S.M.I.G. We studied 90 lung cancer patients according to the S.M.I.G. classification and we observed that their prognoses were directly correlated with their S.M.I.G. scores (the higher the score, the higher the 10-month mortality rate). The mortality rates within the first 10 months of follow-up were respectively 0%, 0%, 36.36%, 68%, 90.9% for the 5 groups obtained by S.M.I.G. The difference is statistically significant (P < 0.0075) and there is a linear correlation between the mortality rate and the score assigned to each group (R = 0.943; P < 0.05). The S.M.I.G. classification can predict the prognosis more efficiently than the usual classification (TNM) and histological cell type.
Collapse
|
3
|
Abstract
Since its identification in seminal fluid in 1971, much new information has been obtained about the biology and expression of prostate-specific antigen (PSA). PSA is a glycoprotein composed of 93% amino acids and 7% carbohydrates, with a molecular weight of about 30,000 Da. Functionally and structurally PSA is a kallikrein-like serine protease, and its physiologic role is degradation of the major proteins of seminal coagulum (semenogelin I and II, fibronectin), which leads to semen liquefaction. The PSA gene is located on the 13q region of chromosome 19, and it has a high degree of homology (more than 80%) with genes of the human glandular kallikrein (hKGK1). PSA production and expression are preferentially but not exclusively associated to the normal, benign hyperplastic and cancerous tissues of the prostate. In fact, it has been demonstrated that PSA is also present in accessory male sex glands and breast cancer. It was recently reported that PSA was also present in milk of lactating women. Many factors may influence PSA synthesis and production, and among them the most important are androgen, retinoic acid and growth factor stimulation. Significant advances have been recently made as regards the molecular isoforms of PSA. In the seminal fluid PSA seems partially bound to a serpine (protein C inhibitor), whereas in serum it is predominantly associated to α-1-antichymotrypsin and in a small quantity to α-2-macroglobulin. These new findings will have implications for the clinical application of PSA as a tumor marker for prostate cancer.
Collapse
Affiliation(s)
- E Seregni
- Nuclear Medicine Department, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy
| | | | | | | |
Collapse
|
4
|
Alò PL, Visca P, Trombetta G, Mangoni A, Lenti L, Monaco S, Botti C, Serpieri DE, Di Tondo U. Fatty Acid Synthase (Fas) Predictive Strength in Poorly Differentiated Early Breast Carcinomas. Tumori 2018; 85:35-40. [PMID: 10228495 DOI: 10.1177/030089169908500108] [Citation(s) in RCA: 89] [Impact Index Per Article: 14.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Aims and background Many normal and human cancer tissues express fatty acid synthase (FAS), the major enzyme required for endogenous fatty acid biosynthesis. Strong expression of FAS seems to be associated with a poor prognosis. This study examines the strength of FAS and other common markers of relapse in poorly differentiated breast carcinoma. Materials and methods Fifty-one patients with poorly differentiated ductal infiltrating breast carcinomas were followed up for more than 10 years. Immunohistochemical detection of FAS was associated with morphological features of the tumors, with immunohistochemical expression of c-erbB-2, cathepsin D, estrogen and progesterone receptor status and with DNA ploidy in order to detect a statistical correlation. Results The chi-square test revealed a correlation between FAS and peritumoral lymphatic vessel invasion (PLVI) (P = 0.001). Univariate analysis showed that FAS was correlated with disease-free survival (DFS) (P = 0.0001). Other prognosticators associated with DFS were PLVI (P = 0.002), estrogen (P = 0.008) and progesterone receptor status (P = 0.007). Bivariate analysis showed that FAS was a further prognostic discriminant of DFS within the ER, PgR and PLVI subsets. Discussion FAS is a reliable prognosticator of recurrence in poorly differentiated early breast carcinomas. Association of FAS with PLVI may be useful to plan a correct follow-up in patients with breast neoplasms.
Collapse
Affiliation(s)
- P L Alò
- Dipartimento di Medicina Sperimentale e Patologia, Università di Roma La Sapienza, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Affiliation(s)
- E Seregni
- Nuclear Medicine Division, National Cancer Institute, Milan, Italy
| | | | | | | | | | | | | |
Collapse
|
6
|
Abstract
In this review the main characteristics, i.e., structure, function and gene expression, of the different mucins are discussed. Mucin-type molecules consist of a core protein moiety (apomucin) where a number of carbohydrate chains are attached to serines and threonines by glycosidic bonds. O-linked carbohydrates form up to 80% of the molecule and the length of the glucidic side chains varies from one to more than 20 residues. At least eight mucin-like genes have been isolated so far, and the main characteristic is the presence of a central domain composed of a variable number of “tandem repeats”. The sequence homology of the central domain among the different members of the mucin-type family is limited, indicating that this internal domain is unique for each mucin. Thanks to the integrated results of genetic, immunological and biochemical studies, it is now possible to identify eight apomucin genes, namely MUC1, MUC2, MUC3, MUC4, MUC5AC, MUC5B, MUC6 and MUC7. MUC1 is the best characterized mucin and it is expressed on the apical surface of most polarized epithelial cells. The MUC1 gene has been cloned and sequenced. The MUC2 gene encodes a typical secretory gel-forming mucin which represents the predominant form in human intestinal and colon tissues. Another intestinal mucin is MUC3. The MUC4, MUC5AC and MUC5B genes have been isolated from a bronchial tissue cDNA library. The MUC4 and MUC5AC genes are mainly expressed in the respiratory tract, in gastric and reproductive mucosa, while MUC5B is highly detectable only in the bronchial glands. The MUC6 gene is expressed by gastric tissue and, recently, MUC7 has been cloned and sequenced using a salivary cDNA library.
Collapse
Affiliation(s)
- E Seregni
- Nuclear Medicine Department, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan
| | | | | | | | | | | | | |
Collapse
|
7
|
Affiliation(s)
- L Maffioli
- Nuclear Medicine Division, National Cancer Institute, Milan, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Abstract
Bladder cancer shows extreme variability in its behavior. Even the superficial forms, when surgically treated, are characterized by a high recurrence rate, and therefore regular and intensive post-treatment monitoring is an important aspect of the management of this tumor. The standard follow-up of patients with a bladder cancer history is based on cystoscopic examination of the internal bladder, which is an invasive procedure causing discomfort to the patient. In this context, the availability of a non-invasive laboratory test which measures circulating markers associated with bladder cancer could facilitate the monitoring of patients and could be of help in understanding the metastatic potential of bladder tumors, especially the superficial forms.
Collapse
Affiliation(s)
- C Botti
- Nuclear Medicine Department, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano
| | | | | | | | | | | |
Collapse
|
9
|
Botti C, Seregni E, Menard S, Tagliabue E, Bonanate A, Cantarella D, Lombardo C, Massaron S, Martinetti A, Ferrari L, Ghirelli C, Aiello P, Bombardieri E. Production of a Novel Monoclonal Antibody against Muc4 Mucin. Int J Biol Markers 2018. [DOI: 10.1177/172460089701200108] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Affiliation(s)
- C. Botti
- Department of Nuclear Medicine, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano - Italy
| | - E. Seregni
- Department of Nuclear Medicine, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano - Italy
| | - S. Menard
- Department of Experimental Oncology E, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano - Italy
| | - E. Tagliabue
- Department of Experimental Oncology E, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano - Italy
| | - A. Bonanate
- Department of Nuclear Medicine, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano - Italy
| | - D. Cantarella
- Department of Nuclear Medicine, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano - Italy
| | - C. Lombardo
- Department of Immunohematology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano - Italy
| | - S. Massaron
- Department of Nuclear Medicine, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano - Italy
| | - A. Martinetti
- Department of Nuclear Medicine, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano - Italy
| | - L. Ferrari
- Department of Nuclear Medicine, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano - Italy
| | - C. Ghirelli
- Department of Experimental Oncology E, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano - Italy
| | - P. Aiello
- Department of Experimental Oncology E, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano - Italy
| | - E. Bombardieri
- Department of Nuclear Medicine, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano - Italy
| |
Collapse
|
10
|
|
11
|
Martinetti A, Seregni E, Bajetta E, Bolelli G, Ferrari L, Massaron S, Botti C, Bombardieri E. Development of a Rapid and Ultrasensitive RIA Method for Estrogen (E2, E1, E1-S) Determination with Selective Solid Phase Extraction. Int J Biol Markers 2018. [DOI: 10.1177/172460089701200303] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The inhibition of the proliferative stimulation exercised by estrogens on neoplastic cells is the goal of all endocrine therapies in breast cancer. Under various circumstances, e.g. with the use of aromatase inhibitors, this result can be obtained by blocking the synthetic pathway and, consequently, by lowering the circulating levels of estradiol (E2), estrone (E1), and estrone sulfate (E1-S). The evaluation of these hormones in plasma could therefore represent a useful indicator of the biological efficacy of the therapy. However, the measurement of circulating steroids in a large series of patients is often a complicated procedure. Indirect methods of extraction are time consuming and expensive while the analytical sensitivity of direct methods is not sufficient to measure the residual levels of E2, E1, and E1-S. In this paper we describe a novel extraction method for the evaluation of plasma levels of E2, E1, and E1-S. This new method consists of solid phase extraction followed by a highly specific radioimmunoassay. The sensitivity of the assay is 0.6 pg/ml, 2.0 pg/ml and 7.0 pg/ml for E2, E1, and E1-S, respectively.
Collapse
Affiliation(s)
- A. Martinetti
- Nuclear Medicine Division, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy
| | - E. Seregni
- Nuclear Medicine Division, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy
| | - E. Bajetta
- Medical Oncology Division, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy
| | - G.F. Bolelli
- CNR, Reproductive Medicine Unit, Department of Obstetrics and Gynecology, Policlinico S. Orsola, Bologna - Italy
| | - L. Ferrari
- Nuclear Medicine Division, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy
| | - S. Massaron
- Nuclear Medicine Division, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy
| | - C. Botti
- Nuclear Medicine Division, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy
| | - E. Bombardieri
- Nuclear Medicine Division, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy
| |
Collapse
|
12
|
Bombardieri E, Seregni E, Lombardo C, Cantoni A, Bogni A, Botti C, Sfreddo L, Cataldo I. Mucin Gene Expression in Lung Cancer Tissues. Int J Biol Markers 2018; 9:262-3. [PMID: 7836808 DOI: 10.1177/172460089400900414] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
13
|
Botti C, Seregni E, Saccani-Jotti G, Vecchione A, Giarnieri E, Valli C, Menard S, Tagliabue E, Bombardieri E. Preliminary Serological and Immunohistochemical Evaluation of the Reactivity of two Monoclonal Antibodies against MUC4 Mucin. Int J Biol Markers 2018; 12:187-9. [PMID: 9582610 DOI: 10.1177/172460089701200409] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
14
|
Ferrari L, Seregni E, Martinetti A, Van Graafeiland B, Nerini-Molteni S, Botti C, Artale S, Cresta S, Bombardieri E. Chromogranin a Measurement in Neuroendocrine Tumors. Int J Biol Markers 2018; 13:3-9. [PMID: 9681293 DOI: 10.1177/172460089801300102] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Neuroendocrine tumors (NETs) are rare neoplasms characterized by a low proliferative index and, in some cases, a favorable prognosis. These tumors often overproduce and release biologically active substances that are responsible for severe syndromes. Tumor marker measurement provides the clinician with useful information for the management of NET patients. The substances released by overproducing tumors are currently used as biomarkers, but there is a need for sensitive markers also for the “biochemically silent” NETs. The most effective and reliable blood marker available today is chromogranin A (CgA). Because of its high sensitivity and specificity, this glycoprotein can be used for the diagnosis, prognosis and follow-up of NETs. Furthermore, CgA measurement can be used for monitoring those tumors not overproducing or releasing any hormones or biological amines. This paper is a synthetic review on the value of CgA in NET management and reports our experiences with CgA measurement in NET patients.
Collapse
Affiliation(s)
- L Ferrari
- Division of Nuclear Medicine, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Seregni E, Crippa F, Botti C, Bellotti MG, Bogni A, Pizzichetta M, Bombardieri E. Mucin-Like Carcinoma-Associated Antigen (MCA) in Breast Cancer: Clinical Experience at the National Cancer Institute of Milan. Int J Biol Markers 2018; 8:124-9. [PMID: 8366295 DOI: 10.1177/172460089300800209] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Mucin-like Carcinoma-associated Antigen (MCA) is a glycoprotein belonging to the mucin family; it is defined by the monoclonal antibody b-12. Mucins represent an interesting group of tumor markers and are widely utilized in the clinical monitoring of neoplastic patients. These molecules show a certain degree of tissue specificity and MCA is preferentially associated with breast tissue. Several studies have demonstrated that patients with breast cancer usually have high MCA serum levels. In this paper the experience of the National Cancer Institute of Milan with the clinical use of MCA in breast cancer patients is reported. The observed sensitivity of the MCA test was poor in patients with early-stage disease, while it was acceptable in patients with advanced breast cancer. MCA concentrations appeared to be directly related to disease spread. A clear relationship was seen between MCA levels and lymph-nodal status. The highest MCA plasma levels were observed in patients with metastatic disease. In this group of patients the sensitivity of the test on the basis of a cut-off of 11 U/mL was 52%.
Collapse
Affiliation(s)
- E Seregni
- Department of Nuclear Medicine, Istituto Nazionale Tumori, Milano, Italy
| | | | | | | | | | | | | |
Collapse
|
16
|
Mattioli S, Seregni E, Caperna L, Botti C, Savelli G, Bombardieri E. BTA-TRAK Combined with Urinary Cytology is a Reliable Urinary Indicator of Recurrent Transitional Cell Carcinoma (TCC) of the Bladder. Int J Biol Markers 2018. [DOI: 10.1177/172460080001500303] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
This study evaluated the diagnostic accuracy of BTA-TRAK in combination with urinary cytology (UC) in the follow-up of patients with a history of transitional cell carcinoma (TCC) of the bladder. The overall sensitivity of BTA-TRAK, UC and the two tests combined for the detection of recurrences was 82.7% (48/58), 84.2% (48/57) and 91.2% (52/57), respectively. BTA and UC showed comparable sensitivity for superficial recurrences (76.7% (33/43) and 78.5% (33/42), respectively) and for invasive recurrences (100% (15/15)); when the two tests were used in combination, the sensitivity for superficial lesions increased to 88% (37/42). BTA-TRAK was more sensitive than UC for G1 recurrences (81.2% (13/16) vs. 68.7% (11/16)), and when the two tests were combined the sensitivity increased to 87.5% (14/16). The sensitivity of the combination was 100% (15/15) for G3 lesions. The differences in urinary BTA-TRAK levels between patients with recurrences and those without evidence of disease were statistically significant (Wilcoxon's test, p<0.05); among patients with recurrences BTA levels were significantly higher in the invasive and poorly differentiated subtypes. In the series of patients studied by us, BTA-TRAK combined with UC was shown to be a non-invasive, accurate test to predict TCC recurrences. Periodic measurement of BTA-TRAK combined with urinary cytology seems to provide additional information for the monitoring of patients treated for TCC; however, due to the presence of false positive and false negative results, this test cannot replace cystoscopy. In a selected group of patients it could, if combined with cytology and ultrasonography and if correctly used and interpreted, orient the timing and indication for cystoscopy.
Collapse
Affiliation(s)
- S. Mattioli
- Division of Urology, Clinical Institute S. Ambrogio, Milan
| | - E. Seregni
- Division of Nuclear Medicine, National Cancer Institute, Milan - Italy
| | - L. Caperna
- Division of Urology, Clinical Institute S. Ambrogio, Milan
| | - C. Botti
- Division of Nuclear Medicine, National Cancer Institute, Milan - Italy
| | - G. Savelli
- Division of Nuclear Medicine, National Cancer Institute, Milan - Italy
| | - E. Bombardieri
- Division of Nuclear Medicine, National Cancer Institute, Milan - Italy
| |
Collapse
|
17
|
Botti C, Seregni E, Ménard S, Collini P, Tagliabue E, Campiglio M, Vergani B, Ghirelli C, Aiello P, Pilotti S, Bombardieri E. Two Novel Monoclonal Antibodies against the MUC4 Tandem Repeat Reacting with an Antigen Overexpressed by Lung Cancer. Int J Biol Markers 2018; 15:312-20. [PMID: 11192827 DOI: 10.1177/172460080001500406] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
In this study we investigated the immunochemical and cytochemical reactivity of two monoclonal antibodies against the 16-amino acid tandem repeat of MUC4 to demonstrate a possible variation of the mucin core peptide expression related to lung cancer. The immunocytochemical anti-MUC4 reactivity was analyzed in four lung cancer cell lines (Calu-1, Calu-3, H460, SKMES) and in other tumor cell lines, as well as in frozen materials from 21 lung adenocarcinomas (ACs), including five bronchioloalveolar carcinomas (BACs), and 11 squamous cell lung carcinomas (SqCCs). A weak fluorescence anti-MUC4 positivity (range: 10.3–16.2) was observed only in acetone-fixed lung cancer cell lines Calu-1, Calu-3 and H460. These three lung cancer cell lines also showed a cytoplasmic immunoperoxidase reactivity. The immunostaining in lung cancer tissues showed a granular cytoplasmic reactivity: 15/21 (71%) and 17/21 (80%) ACs were positive with BC-LuC18.2 and BC-LuCF12, respectively. All BACs were positive. Moderate to strong reactivity was present in well-differentiated ACs. In the normal lung parenchyma counterparts weak reactivity was found only in bronchiolar cells. All SqCCs were negative. Anti-MUC4 reactivity was also observed in the alveolar mucus. In conclusion, our anti-MUC4 MAbs detect a secretion product present in mucus and this product is elaborated by lung cancer cells and overexpressed in well-differentiated lung ACs.
Collapse
Affiliation(s)
- C Botti
- Division of Nuclear Medicine, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Abstract
Several circulating mucinous markers, including CA 15.3, MCA, CA 459, CASA, and Truquant BR, are secreted products of the polymorphic MUC1 gene, and are used as diagnostic tools in patients with breast cancer. In clinical practice the measurement of the levels of these markers in the blood can give important information on the tumor's response to treatment and its biological behavior during disease monitoring. Since the marker levels reflect the activity of the tumor, it is important to know all factors influencing the production/secretion and the blood concentrations of MUC1 mucin. Recent findings suggest that MUC1 gene expression is regulated by steroid hormones and other substances present in the serum. Such observations are very important not only because of their biological significance but also for their clinical implications, as one approach to breast cancer therapy is based on chemical hormone manipulation. Nevertheless, we have preliminarily demonstrated that endocrine treatment in breast cancer patients does not influence the circulating CA 15.3 serum levels, so changes in marker levels are related only to the clinical evolution of the tumor.
Collapse
Affiliation(s)
- E Seregni
- Nuclear Medicine Department, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy
| | | | | | | | | | | | | |
Collapse
|
19
|
Abstract
The concept of the immunological surveillance against neoplastic cells was initially proposed by Erlich in 1909 and later elaborated by Burnet. This hypothesis states that the normal function of the immune system, in particular the cell-mediated immunity, is to recognize and destroy the transformed and proliferating tumor cells. The role of cell-mediated immunity during the first steps of tumorigenesis remains controversial. However, there is certain evidence about its importance in the progression and dissemination of cancer. The frequent immunosuppressed condition of cancer patients at tumor relapse or recurrence of secondary tumors is a clinical sign supporting this hypothesis, and many studies have demonstrated a defective immune response in patients diagnosed with advanced cancer. Several mechanisms of escape from the immune surveillance have been described, including the immunoselection of tumor antigen-negative variants, the downregulation of MHC class I expression, suppressive T cells, and the elaboration of immunosuppressive cytokines and other factors. Because of the technical difficulty of isolating the very small amounts from culture supernatants or body fluids, only a few of these substances have been characterized and studied with respect to their biological activity: transforming growth factor-β (TGF-β), the protein p15E, interleukin 10 (IL-10), prostaglandin E2 (PGE2), mucins, suppressive E-receptor (SER), immunosuppressive acidic protein (IAP), and adhesion molecules. The possibility of monitoring cancer patients by testing biochemical factors related to cancer growth led to a proposal to measure a number of these factors as tumor markers. Some of them, e.g mucins, enjoy the consensus of the oncologic community, as for some indications they can help the clinician in the management of cancer patients. Except for the class of mucins, the other above-mentioned immunosuppressive factors have not found any clinical application in the laboratory routine because the information deriving from their measurement, although of speculative and scientific interest, has limited clinical value at present. Nevertheless, even if they have no impact on patient management, these substances do have a potential role to play in the study of cancer patients, and should be taken into account when developing new therapeutic strategies.
Collapse
Affiliation(s)
- C Botti
- Nuclear Medicine Department, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy
| | | | | | | | | |
Collapse
|
20
|
Abstract
In the last few years, surgery of the ageing face seems to have shifted from tissue uplifting and tightening to mere filling. We do not agree with this trend. We are positive that ageing brings about 2 basic phenomena: on one hand bone and fat volume reduction, whilst on the other a deterioration of the skin lining (elastosis) leading to an increase in its compliance and extension. We therefore deem of the utmost importance to couple soft tissue filling with indispensable tightening and repositioning together with resection of overabundant skin. For what concerns the mid-face area in particular, we suggest to resort to 3 different lifting techniques, according to the kind of defect to be treated. It is important to take the right pulling vector into consideration as well as the need of skin excess removal. The procedures can be tailored to suit any peculiar need such as malar bag, lower lid border malposition, tear trough deformity, etc. Different cases will be taken into consideration as examples of the various indications and techniques.
Collapse
Affiliation(s)
- G Botti
- Plastic Surgery, Villa Bella Clinic, Saló, Italy
| | - C Botti
- Plastic Surgery, Villa Bella Clinic, Saló, Italy
| |
Collapse
|
21
|
Maione C, Botti C, Coppola CA, Silvestroni C, Lillo S, Schiavone V, Sica G, Sica V, Kumar V, Cobellis G. Effect of autologous transplantation of bone marrow cells concentrated with the MarrowXpress system in patients with critical limb ischemia. Transplant Proc 2013; 45:402-6. [PMID: 23375329 DOI: 10.1016/j.transproceed.2012.10.031] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2012] [Revised: 09/01/2012] [Accepted: 10/09/2012] [Indexed: 10/27/2022]
Abstract
Critical limb ischemia (CLI), a vascular disease affecting lower limbs, with high morbidity and mortality, is becoming a challenge due to the aging of the population. Patients without direct revascularization options have the worst outcomes. To date, 25% to 40% of CLI patients are not candidates for surgical or endovascular approaches, facing a major amputation as the ultimate option. This study sought to assess the safety and efficacy of transplantation of autologous bone marrow concentrates in "no-option" patients to restore blood perfusion by collateral flow and limb salvage. We performed a nonrandomized, noncontrolled pilot study for no-option CLI patients using intra-arterial infusion of autologous bone marrow concentrate. Variation of blood perfusion parameters, evaluated by laser doppler flowmetry after 6 and 12 months, was set as primary endpoint. Thirteen enrolled patients showed improvements in objective measurements of perfusion. This uncontrolled study provided evidence that transplantation of autologous bone marrow concentrates was well tolerated by CLI patients without significant adverse effects, demonstrating improved perfusion, confirming the feasibility and safety of the procedure.
Collapse
Affiliation(s)
- C Maione
- Department of General Pathology, Second University of Naples, Napoli, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Puvabanditsin S, Memon N, Lambert G, Cross G, El-Khawam R, Botti C, Balbin J. Partial trisomy 3p24.3 and partial monosomy 5p15.33: case report and a literature review. Genet Couns 2013; 24:13-20. [PMID: 23610861] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
We report on a preterm neonate with a deletion of the distal short arm of chromosome 5p15.33 and partial trisomy of the distal short arm of chromosome 3p24.3. The patient was the first-born monozygotic twin. There were no pertinent facial or physical features except a small lower lip hemangioma. The neonate presented with cardiac defects, which included a patent ductus arteriosus, an atrial septal defect and ventricular septal defects. After 94 days of age, however, the patient died from superior vena cava syndrome, recurrent chylothoraces and generalized anasarca. Array comparative genomic hybridization (aCGH) using a custom oligonucleotide microarray (Agilent 180,000 probe platform revealed a terminal duplication of 1,128 oligonucleotide probes from 3pter to 3p24.3, spanning approximately 20.4 megabases (Mb), and a terminal deletion of 271 oligonucleotide probes from 5pter to 5p15.33, spanning approximately 4.3 Mb. This is the first report of a patient with partial trisomy 3p24.3 and partial monosomy 5p15.33 without major dysmorphic features.
Collapse
MESH Headings
- Chromosome Deletion
- Chromosomes, Human, Pair 3/genetics
- Chromosomes, Human, Pair 5/genetics
- Chylothorax/complications
- Chylothorax/diagnosis
- Comparative Genomic Hybridization/methods
- Diseases in Twins/diagnosis
- Diseases in Twins/genetics
- Ductus Arteriosus, Patent/complications
- Ductus Arteriosus, Patent/diagnosis
- Edema/complications
- Edema/diagnosis
- Fatal Outcome
- Female
- Heart Defects, Congenital/complications
- Heart Defects, Congenital/diagnosis
- Heart Septal Defects, Atrial/complications
- Heart Septal Defects, Atrial/diagnosis
- Heart Septal Defects, Ventricular/complications
- Heart Septal Defects, Ventricular/diagnosis
- Humans
- Infant
- Infant, Newborn
- Infant, Premature
- Oligonucleotide Array Sequence Analysis/methods
- Superior Vena Cava Syndrome/complications
- Superior Vena Cava Syndrome/diagnosis
- Trisomy/diagnosis
- Trisomy/genetics
- Twins, Monozygotic
Collapse
Affiliation(s)
- S Puvabanditsin
- Department of Pediatrics, UMDNJ-Robert Wood Johnson, Medical School, New Brunswick, New Jersey 08903, USA.
| | | | | | | | | | | | | |
Collapse
|
23
|
Seregni E, Foa P, Bogni A, Botti C, Cataldo I, Sala M, Mezzetti M, Gasparini M, Santambrogio L, Legnani D, Bombardieri E. Evaluation of the soluble fragments of cytokeratin 19 (CK19) in non-small cell lung cancer (NSCLC). Oncol Rep 2012; 3:95-101. [PMID: 21594322 DOI: 10.3892/or.3.1.95] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
This study compared the diagnostic efficacy of serum CK19 determination (Cyfra 21-1) with other tumour markers, such as CEA, SCC, NSE, TPA, in patients with resected non-small lung cancer. Tumour marker levels were tested in 90 patients with benign lung disease and at diagnosis in 72 patients with proven NSCLC, 39 squamous cell carcinoma and 33 adenocarcinoma. At presentation baseline levels of all tumor markers were significantly higher (p<0.05) in lung cancer patients than in control subjects, except for NSE. A significant increase (p<0.05) in serum concentrations was observed from stage I to stage IIIb only for Cyfra 21-1 (stage I/II, median=2.7 ng/ml; stage IIIb, median=6.3 ng/ml) and TPA (stage I/II, median=89.8 IU/ml; stage IIIb, median=170.7 IU/ml). Receiver operating characteristic (ROC) analysis was performed to evaluate the best threshold values and the global accuracy of each marker. The highest global sensitivity for NSCLC was reached by TPA (70.8%), whereas that of Cyfra 21-1 was 50%. According to tumour histology, significant difference (p<0.05) in serum levels were found only for CEA (adenocarcinomas, median=5.6 ng/ml; squamous cell carcinoma, median=3.2 ng/ml) and SCC (adenocarcinomas, median=1.0 ng/ml; squamous cell carcinoma, median=1.5 ng/ml). As regards squamous cell carcinoma histotype, the highest sensitivity was obtained by TPA (74.4% at a specificity of 62.2%) and for adenocarcinomas by CEA (78.8% at a specificity of 85.6%). Tumour marker levels were also determined during the follow-up of 10 patients. The best sensitivity in detecting relapses was shown by CEA (90%), followed by TPA (70%), SCC (50%), Cyfra 21-1 (40%) and NSE (10%), even though the CEA test displayed a high percentage of false positive results (98.1%) in patients with no evidence of disease (NED).
Collapse
Affiliation(s)
- E Seregni
- IST NAZL STUDIO & CURA TUMORI,DIV NUCL MED,MILAN,ITALY. UNIV MILAN,IST SCI MED,MILAN,ITALY. IST NAZL STUDIO & CURA TUMORI,DIV ONCOL CHIRURG TORACICA,MILAN,ITALY. ICP,CTR TRANSFUS CLIN MANGIAGALLI,MILAN,ITALY. UNIV MILAN,CATTEDRA CHIRURG GEN & TORACICA,MILAN,ITALY. UNIV MILAN,IST MALATTIE RESP,MILAN,ITALY
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Abstract
Inadequate blood supply to tissues caused by obstruction of arterioles and/or capillaries results in ischemic injuries – these injuries can range from mild (eg, leg ischemia) to severe conditions (eg, myocardial infarction, stroke). Surgical and/or endovascular procedures provide cutting-edge treatment for patients with vascular disorders; however, a high percentage of patients are currently not treatable, owing to high operative risk or unfavorable vascular involvement. Therapeutic angiogenesis has recently emerged as a promising new therapy, promoting the formation of new blood vessels by the introduction of bone marrow–derived stem and progenitor cells. These cells participate in the development of new blood vessels, the enlargement of existing blood vessels, and sprouting new capillaries from existing blood vessels, providing evidence of the therapeutic utility of these cells in ischemic tissues. In this review, the authors describe peripheral arterial disease, an ischemic condition affecting the lower extremities, summarizing different aspects of vascular regeneration and discussing which and how stem cells restore the blood flow. The authors also present an overview of encouraging results from early-phase clinical trials using stem cells to treat peripheral arterial disease. The authors believe that additional research initiatives should be undertaken to better identify the nature of stem cells and that an intensive cooperation between laboratory and clinical investigators is needed to optimize the design of cell therapy trials and to maximize their scientific rigor. Only this will allow the results of these investigations to develop best clinical practices. Additionally, although a number of stem cell therapies exist, many treatments are performed outside international and national regulations and many clinical trials have been not registered on databases such as ClinicalTrials.gov or EudraCT. Therefore, more rigorous clinical trials are required to confirm the first hopeful results and to address the challenging issues.
Collapse
Affiliation(s)
- C Botti
- Department of General Pathology, Second University of Naples, Naples, Italy
| | | | | | | | | |
Collapse
|
25
|
Vici P, Pizzuti L, Mottolese M, Sergi D, Di Benedetto A, Botti C, Perracchio L, Pescarmona E, Carpino A, Di Lauro L. Phase II Trial of Primary Systemic Therapy (PST) with Docetaxel (D) Followed by High-Dose Epirubicin in Combination with Cyclophosphamide (EC) Plus Concurrent Trastuzumab (T) For Stage II-III HER-2 Positive Breast Cancer Patients (PTS). Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)32973-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
26
|
Barba M, Sperati F, Stranges S, Carlomagno C, Nasti G, Iaffaioli V, Caolo G, Mottolese M, Botti G, Terrenato I, Vici P, Serpico D, Giordano A, D’Aiuto G, Crispo A, Montella M, Capurso G, Delle Fave G, Fuhrman B, Botti C, De Placido S. Fasting glucose and treatment outcome in breast and colorectal cancer patients treated with targeted agents: results from a historic cohort. Ann Oncol 2012; 23:1838-45. [PMID: 22100694 PMCID: PMC3387821 DOI: 10.1093/annonc/mdr540] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2011] [Revised: 10/03/2011] [Accepted: 10/05/2011] [Indexed: 12/29/2022] Open
Abstract
BACKGROUND We investigated pretreatment fasting glucose as a predictor of patients' important outcomes in breast and colorectal cancers undergoing targeted therapies. PATIENTS AND METHODS In a historic cohort of 202 breast and 218 colorectal cancers treated with targeted agents from 1998 to 2009, we used the Kaplan-Meier method and the log-rank test to estimate survival through tertiles of fasting glucose and the Cox proportional hazards model for multivariate analysis stratified by primary site of cancer and including gender, age and body mass index. RESULTS The median follow-up was 20 months (1-128). At 60 months, 65% of patients in the lowest tertile of fasting glucose did not experiment disease progression compared with 34% in the highest tertile (P=0.001). Seventy-six percent of females in the lowest tertile showed no progression compared with 49% in the top tertiles (P=0.015). In multivariate analysis, fasting glucose was a significant predictor of time to disease progression only in breast cancer patients in the first tertile compared with the third (P=0.017). CONCLUSIONS We found evidence of a predictive role of pretreatment fasting glucose in the development of resistance in breast cancer patients treated with targeted agents. Prospective studies are warranted to confirm our findings.
Collapse
Affiliation(s)
- M. Barba
- Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, Temple University, Philadelphia, USA
- Human Health Foundation, Spoleto-Terni
| | - F. Sperati
- Department of Epidemiology, Regina Elena National Cancer Institute, Rome, Italy
| | - S. Stranges
- Health Sciences Research Institute, University of Warwick Medical School, Coventry, UK
| | - C. Carlomagno
- Department of Medical Oncology and Endocrinology, Federico II Medical School of Naples, Naples
| | - G. Nasti
- Department of Colorectal Medical Oncology, G. Pascale National Cancer Institute, Naples
| | - V. Iaffaioli
- Department of Colorectal Medical Oncology, G. Pascale National Cancer Institute, Naples
| | - G. Caolo
- Department of Epidemiology, Regina Elena National Cancer Institute, Rome, Italy
| | - M. Mottolese
- Department of Pathology, Regina Elena National Cancer Institute, Rome
| | - G. Botti
- Departmental Unit of Pathology and Cytopathology, G. Pascale National Cancer Institute, Naples
| | - I. Terrenato
- Department of Epidemiology, Regina Elena National Cancer Institute, Rome, Italy
| | - P. Vici
- Division of Medical Oncology B, Regina Elena National Cancer Institute, Rome; Departments of
| | - D. Serpico
- Department of Medical Oncology and Endocrinology, Federico II Medical School of Naples, Naples
| | - A. Giordano
- Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, Temple University, Philadelphia, USA
- Human Health Foundation, Spoleto-Terni
| | | | - A. Crispo
- Epidemiology, G. Pascale National Cancer Institute, Naples
| | - M. Montella
- Epidemiology, G. Pascale National Cancer Institute, Naples
| | - G. Capurso
- Digestive and Liver Disease Unit, II Medical School, University La Sapienza, Rome
| | - G. Delle Fave
- Digestive and Liver Disease Unit, II Medical School, University La Sapienza, Rome
| | - B. Fuhrman
- Department of Epidemiology, Regina Elena National Cancer Institute, Rome, Italy
| | - C. Botti
- Department of Surgery, Regina Elena National Cancer Institute, Rome, Italy
| | - S. De Placido
- Department of Medical Oncology and Endocrinology, Federico II Medical School of Naples, Naples
| |
Collapse
|
27
|
Botti C, Maione C, Dogliotti G, Russo P, Signoriello G, Molinari AM, Corsi MM, Sica V, Cobellis G. Circulating cytokines present in the serum of peripheral arterial disease patients induce endothelial dysfunction. J BIOL REG HOMEOS AG 2012; 26:67-79. [PMID: 22475098] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
Peripheral arterial disease (PAD) is a chronic condition caused by atherosclerosis and is a severe complication of type 2 diabetes (T2D). We hypothesised that chronic condition of arterial disease engenders inflammation and endothelial damage in response to circulating cytokines released in the blood stream of PAD patients. We explored the levels of circulating cytokines in PAD patients with and without diabetes by multiplex cytokine array compared with non-PAD controls. Serum from PAD patients with or without diabetes showed high levels of VEGF, IFN-gamma, TNF-alpha, MCP-1, and EGF. VEGF levels correlated with TNF-alpha and IFN-gamma, significantly. Endothelial cells (ECs) were exposed to the different altered cytokines to evaluate changes in cell growth, migration and tubule-like formation, displaying impairment on proliferation, migration and tubule formation. Our findings demonstrate that a set of cytokines is significantly increased in the serum of PAD patients. These cytokines act to induce endothelial dysfunction synergistically. VEGF strongly correlated with TNF-alpha and IFN-gamma, opening new therapeutic perspectives.
Collapse
Affiliation(s)
- C Botti
- Department of General Pathology, Second University of Naples, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Di Filippo F, Casini B, Gallo E, Terrenato I, Botti C, Mottolese M, Pescarmona E, Marandino F, Buglioni S. P3-07-02: Prediction of Non-Sentinel Lymph Node Status in Breast Cancer Patients with a Micrometastatic Sentinel Lymph Node Determined by the One Step Nucleic Acid Amplification (OSNA) Assay. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p3-07-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Axillary lymph node dissection (ALND) may not be necessary in women with breast cancer (BC) who have micrometastasis in a sentinel lymph node (SLN), owing to the low risk of non-SLN (NSLN) involvement. In our Institute we validated and adopted the new molecular diagnostic tool OSNA (One Step Nucleic Acid Amplification) based on the quantitative measurement of Cytokeratin 19 (CK19) mRNA. The aims of our work in a subgroup of women with micrometastatic SLN, were: 1) to correlate the copy numbers of CK19 mRNA with the risk of additional positive NSLNs; 2) to assess the relationships between the molecular subtype classification based on the immunohistochemistry phenotypic patterns and the probability of a positive ALND; 3) to verify whether a combination of the new above mentioned parameters is able to identify a subgroup of patients with a micrometastatic SLN and a negligible risk of positive NSLNs in whom ALND may be avoided.
Material and Methods: The intraoperative clinical study was conducted on 901 fresh SLNs from 709 consecutive patients with clinically node negative BC. The SLN lysates were analyzed by OSNA assay. If the CK19 mRNA copy number/mL lysate was less than 250 copies/mL, the result was regarded as negative (−); copy numbers between 250 and 5000/mL were regarded as micrometastasis (+), and copy numbers greater than 5000/mL as macrometastasis (++). We analyzed only patients with a micrometastatic SLN. Complementary ALND was performed concurrently in case of OSNA assay positivity and the probability of having a positive lymph node axillary dissection was calculated by the unconditional logistic regression model. This series of BC patients were divided into four main subtypes taking in account the BC classification as defined by a combination of estrogen, progesteron receptors and HER2 status evaluated by immunohistochemistry (IHC) and confirmed by FISH in case of IHC-HER2 2+.
Results: OSNA positivity for micrometastasis was reported in 91/709 cases (12,8%).The number of patients with positive ALND was 20 (22%). The statistical analyses showed that the metastatic involvement of NSLNs is associated with SLNs with a high copy numbers (>2000) of CK19 mRNA together with luminal B subtype. Otherwise none of the luminal A patients with a positive SLN but presenting a copy number <1000, had a positive NSLNs.
Conclusions: We showed that biologically-driven analyses may be able to build new models with higher performance in terms of breast cancer axillary status prediction after positive SLN biopsy for micrometastasis. The copy numbers of CK19 mRNA and the molecular subtypes are more advantageous than traditional parameters because they are not pathologist-dependent and therefore they are more reliable and reproducible.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P3-07-02.
Collapse
Affiliation(s)
- F Di Filippo
- 1Regina Elena National Cancer Institute, Rome, Italy; Regina Elena National Cancer Institute, Italy
| | - B Casini
- 1Regina Elena National Cancer Institute, Rome, Italy; Regina Elena National Cancer Institute, Italy
| | - E Gallo
- 1Regina Elena National Cancer Institute, Rome, Italy; Regina Elena National Cancer Institute, Italy
| | - I Terrenato
- 1Regina Elena National Cancer Institute, Rome, Italy; Regina Elena National Cancer Institute, Italy
| | - C Botti
- 1Regina Elena National Cancer Institute, Rome, Italy; Regina Elena National Cancer Institute, Italy
| | - M Mottolese
- 1Regina Elena National Cancer Institute, Rome, Italy; Regina Elena National Cancer Institute, Italy
| | - E Pescarmona
- 1Regina Elena National Cancer Institute, Rome, Italy; Regina Elena National Cancer Institute, Italy
| | - F Marandino
- 1Regina Elena National Cancer Institute, Rome, Italy; Regina Elena National Cancer Institute, Italy
| | - S Buglioni
- 1Regina Elena National Cancer Institute, Rome, Italy; Regina Elena National Cancer Institute, Italy
| |
Collapse
|
29
|
Pino MS, Fabi A, Tedeschi M, Mottolese M, Papaldo P, Vici P, Ferretti G, Nisticò C, Russillo M, Cuppone F, Di Benedetto A, Botti C, Giannarelli D, Cognetti F. Biological markers to predict response to neoadjuvant chemotherapy (NCT) in patients with locally advanced breast cancer (LABC): Ready for prime time? J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e11073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
30
|
Vici P, Sergi D, Pizzuti L, Vincenzoni C, Vizza E, Tomao F, Morace N, Toglia G, Mancini E, Baiocco E, Di Lauro L, Botti C, Sindico S, Lopez M. [Specificity of action of anticancer agents]. Clin Ter 2011; 162:137-149. [PMID: 21533321] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
Since the first cancer chemotherapy use, efforts have been made in identifying drugs with an antitumor specific action, but cancer is a very complex situation to be cured with a single agent, and to increase drugs selective cytotoxicity new agent combinations, or innovative cellular cycle related schedule, or the use of pro-drugs have been developed. Notwithstanding some relevant improvements in results, chemotherapy remains often a palliative approach. The improved knowledge of the biology of cancer, and of molecular mechanisms and specific targets, has recently modified the approach to various tumors. In particular, the identification of a single and specific genetic alteration in some tumors such as myeloid chronic leukaemia or gastrointestinal stromal tumors (GIST) led to the development of imatinib, a "target" drug with a multikinase inhibitor activity towards the specific genetic alteration; this unique opportunity is not applicable to other tumors, because usually tumors have multiple genetic alterations with very complex molecular pathways. The development of drugs with a multitarget action is probably the best approach to the majority of human cancers, but other possibility are the combination of multiple agents, each with known selective activity towards a specific molecular target, or the choice of a chemotherapic drug in combination with one or more molecularly targeted drugs. The knowledge of the multiple and extremely complex molecular pathways of the neoplastic cells will hopefully drive oncologic science towards a more "exact" science, with the use of "personalized" treatment in each cancer patient.
Collapse
Affiliation(s)
- P Vici
- Divisione di Oncologia Medica B, Istituto Nazionale Tumori Regina Elena, Roma, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Puvabanditsin S, Garrow E, Lambert G, Botti C, Gowda S, Kathiravan S, Brooks SS. Partial trisomy 10p12.33 and partial monosomy 13q32.1: case report and a literature review. Genet Couns 2011; 22:263-272. [PMID: 22029167] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
We report on a preterm neonate with a deletion of the distal long arm of chromosome 13q32.1 and partial trisomy of the short arm of chromosome 10p12.33. The patient has intrauterine growth retardation, microphthalmia, macrocephaly, holoprosencephaly, patent ductus arteriosus, aortic isthmus hypoplasia, right renal agenesis, imperforate anus, ambiguous genitalia, pleural effusion and vertebral anomaly. Analysis using an oligonucleotide microarray (U-array Cyto6000 array platform (Human Genome build: hg 18) indicated that there was a partial trisomy of chromosome 10(19.5 Mb gain) involving 298 oligonucleotides from 10pter to 10p12.33, and a partial monosomy of chromosome 13(18.3 Mb deleted) involving 313 oligonucleotides from 13q32.1 to 13qter. This is the first report of a patient with partial trisomy 10p12.33 and partial monosomy 13q32.1.
Collapse
Affiliation(s)
- S Puvabanditsin
- Department of Pediatrics, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, New Jersey 08903, USA.
| | | | | | | | | | | | | |
Collapse
|
32
|
Buglioni S, Casini B, Marandino F, Terrenato I, Gallo E, Perri P, Botti C, Maini CL, Di Filippo F. Abstract P1-01-09: Molecular Detection of Sentinel Lymph Node Metastases in Breast Cancer Patients: Correlation between Cytokeratin 19 mRNA Copy Number Detected by One Step Nucleic Acid Amplification (OSNA) and Risk of Metastases in Axillary Lymph Nodes. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p1-01-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The accuracy of the OSNA assay for metastases detection in sentinel lymph nodes (SLNs) has recently been validated in our Institute and adopted as an intra-operative test for breast cancer (BC) patient management. The aims of this study in a series of early BC patients, were: 1) to correlate the copy numbers of cytokeratin 19 (CK19) mRNA with the size of nodal metastases and with the risk of additional disease in non-sentinel lymph nodes (NSLNs); 2) to investigate the relationship between SLN status with OSNA method, and conventional bio-pathological factors taking into account the molecular BC classification: luminal A, luminal B, HER2 subtype, and triple-negative; 3) to identify a subgroup of patients with positive SLN with higher risk of NSLNs metastatic involvement. Material and Methods: 750 SLNs from 580 patients were clinically processed using both OSNA assay and post-operative histology. The results of these two methods were then compared. The correlation between the size of metastases and the copy numbers of CK19 mRNA was calculated using the Spearman correlation coefficient. Complementary axillary lymph node dissection (ALND) was performed concurrently in case of OSNA assay positivity and the probability of having a positive lymph node axillary dissection was calculated by the unconditional logistic regression model. This series of BC patients were divided into four main subtypes taking in account the BC classification based on the immunohistochemistry phenotypic patterns.
Results: OSNA positivity was reported in 24.6% of the patients for a sensitivity of 94.2%. Considering the 145 patients with SLN positivity the size of metastatic foci was significantly correlated to the copy numbers of CK19 mRNA. The complex relationships among the bio-pathological variables analyzed by multiple correspondence analysis (MCA) showed that the metastatic involvement of NSLNs is associated with SLNs with a high copy numbers of CK19 mRNA and HER2 subtype tumors. OSNA specificity (95%) and negative predictive value (98.4%) clearly demonstrated its reliability to guide ALND decision. Conclusions: Our results showed that OSNA is an excellent method for the detection of metastases in SLN and its adoption in our clinical practice has determined a significant improvement in the diagnosis of metastatic BC.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P1-01-09.
Collapse
Affiliation(s)
- S Buglioni
- Regina Elena Cancer Institute, Rome, Italy
| | - B Casini
- Regina Elena Cancer Institute, Rome, Italy
| | | | | | - E Gallo
- Regina Elena Cancer Institute, Rome, Italy
| | - P Perri
- Regina Elena Cancer Institute, Rome, Italy
| | - C Botti
- Regina Elena Cancer Institute, Rome, Italy
| | - CL Maini
- Regina Elena Cancer Institute, Rome, Italy
| | | |
Collapse
|
33
|
Mottolese M, Melucci E, Dimartino V, Conti S, Di Benedetto A, Fabi A, Nisticò C, Ercolani C, Antoniani B, Perracchio L, Vici P, Botti C. Abstract P2-06-10: Loss of Heterozygosity of an Intron 1 Polymorphic Sequence of Epidermal Growth Factor Receptor in Basal-Like Breast Cancer and Tumor-Adjacent Normal Tissue. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p2-06-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Breast cancer (BC) is currently regarded as a heterogeneous disease classified, through gene expression analysis, into various molecular subtypes with different biological characteristics and clinical behaviour. Using a few protein biomarkers as estrogen, progesterone and HER2 receptors, BC subtypes can be divided in four main groups: luminal A, luminal B, HER2 and triple negative (TN). Triple negative BC are a heterogeneous subset of tumors grouped together on the basis of their lack of hormone receptor and HER2 expression. Although they demonstrate similarities in terms of pathological and molecular characteristics, they do not represent a uniform clinical entity since the expression of the basal cytokeratin (CK5) and EGFR may identify a subgroup, called basal-like, of very aggressive tumors encompassing about 10% of BC that display a particularly poor prognosis. Recently, in vitro and in vivo studies reported that the length of a CA Simple Sequence Repeat 1 (CASSRI) dinucleotides in the intron 1 of egfr was associated with the expression of EGFR. In addition, the loss of heterozigosity (LOH) within this region would also lead to altered receptor expression. In this study we aimed to determine the association between LOH and overexpression of EGFR in a series of basal-like BC and their in autologous uninvolved peritumoral tissues (PTT) in comparison to normal tissues (NT).
Material and Methods: 35 TN BC, the correspondent PTT and the autologous NT were analyzed for EGFR, CK5 expression by immunohistochemistry (IHC) and for LOH using a fragment separation performed by capillary electrophoresis (ABI 3130 Applied Biosystem). The assessment of LOH on the three tissue substrates were evaluated comparing the peak area of the two alleles using the following equation: LOH score=T1XN2/T2XN1, where T is BC or PTT, N is normal tissue, 1 is the area under the peak corresponding to the shorter allele, and 2 to the longer allele. The result was significantly different from the ratio of the normal allele peak areas when the LOH score was < 0.79 (loss of the longer allele) or >1.27 (loss of the shorter allele). Results: Of the 35 TN BC, 29 (83%) expressed EGFR and/or CK5 and were defined basal-like BC. The remaining 6 (17%) cases, negative both for EGFR and CK5, were excluded from the study. Of the 16 EGFR positive basal-like BC, 10 (63%) showed LOH whereas of the 13 EGFR negative basal-like BC, only 3 (23%) showed LOH (p=0.03). Although in the majority basal-like BC with LOH (8/10; 80%) PTT displayed a genetic profile similar to NT and did not show LOH, interestingly, in 2 cases (20%) PTT is different from NT presenting LOH and expressing EGFR as the autologous BC.
Conclusions: Our data indicate that LOH of CASSRI in the intron 1 of egfr is related to EGFR expression in basal-like BC. In addition, the evidence of LOH in PTT, denoting the occurrence of early molecular alterations in histologically normal tissues, could represent a potential biomarker with diagnostic/prognostic implications. Supported by AIRC
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P2-06-10.
Collapse
Affiliation(s)
| | - E Melucci
- Regina Elena Cancer Institute, Rome, Italy
| | | | - S Conti
- Regina Elena Cancer Institute, Rome, Italy
| | | | - A Fabi
- Regina Elena Cancer Institute, Rome, Italy
| | - C Nisticò
- Regina Elena Cancer Institute, Rome, Italy
| | - C Ercolani
- Regina Elena Cancer Institute, Rome, Italy
| | | | | | - P Vici
- Regina Elena Cancer Institute, Rome, Italy
| | - C. Botti
- Regina Elena Cancer Institute, Rome, Italy
| |
Collapse
|
34
|
Cobellis G, Botti C, Taddeo A, Silvestroni A, Lillo S, Da Ponte A, Villa M, Sica V, Della Bella S. Successful Bone Marrow Transplantation Reveals the Lack of Endothelial Progenitor Cells Mobilization in a Patient With Critical Limb Ischemia: A Case Report. Transplant Proc 2010; 42:2816-20. [DOI: 10.1016/j.transproceed.2010.04.047] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2009] [Revised: 12/12/2009] [Accepted: 04/08/2010] [Indexed: 12/25/2022]
|
35
|
Di Filippo F, Mottolese M, Botti C, Marandino F, Psaila A, Perri P, Di Filippo S, Pasqualoni R, Ferranti F, Buglioni S. A prospective clinical study for molecular intra-operative detection of lymph node metastasis in breast cancer patients by one step nucleic acid amplification (OSNA) in comparison to intensive histological investigation. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.609] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
609 Background: The aims of the study were 1) to assess the accuracy of a new intra-operative molecular diagnostic tool named OSNA, based on the measurement of cytokeratin 19 (CK19) mRNA, in the detection of axillary sentinel lymph node (SLN) metastases in patients with breast carcinoma 2) to determine the concordance of OSNA analysis with multilevel haematoxylin and eosin (H&E) and immunohistochemical (IHC) examination. Methods: A prospective series of 247 consecutive SLNs from 187 breast cancer patients was evaluated. The OSNA assay (Sysmex, Kobe - Japan) follows a short sample preparation step and subsequent rapid amplification of CK19 mRNA based on reverse transcription loop-mediated isothermal amplification. Each SLN was immediately divided into four slices. Two alternate slices were used for the intra-operative OSNA assay. The remaining two slices were investigated by six-level histopathology with 100 μm skip ribbons using routine H&E and CK19 IHC staining. The results of histology and OSNA were then compared. Results: Pts characteristics: infiltrating ductal/infiltrating lobular/mucinous/medullar/DCIS: 130/10/1/1/25. OSNA and histo-pathological methods identified 54 SLNs positive and 185 negative cases (2/3 contained isolated tumour cells). We found 8 discordant cases, 2 OSNA negative with micrometastasis found by IHC/H&E analysis, 5 OSNA positive for micrometastases but IHC/H&E negative and 1 case macrometastatic at OSNA, while negative at IHC/H&E analysis. The overall concordance of OSNA with histopathology was 96.7% with a specificity of 96.8% and sensitivity of 96.4%. These discordances could be due to sampling bias such that a micrometastasis was confined to the slices used for OSNA or the slices used for histology. Conclusions: The current study suggests that the performance provided by OSNA assay is comparable to intensive histopathological work-up even when using only half a lymph node. The method could be applied as a rapid and reliable intra-operative diagnostic tool thus preventing breast cancer patients from a diagnostic delay or second surgery due to a postoperatively diagnosed positive SLN. No significant financial relationships to disclose.
Collapse
Affiliation(s)
| | - M. Mottolese
- Regina Elena National Cancer Institute, Rome, Italy
| | - C. Botti
- Regina Elena National Cancer Institute, Rome, Italy
| | - F. Marandino
- Regina Elena National Cancer Institute, Rome, Italy
| | - A. Psaila
- Regina Elena National Cancer Institute, Rome, Italy
| | - P. Perri
- Regina Elena National Cancer Institute, Rome, Italy
| | | | | | - F. Ferranti
- Regina Elena National Cancer Institute, Rome, Italy
| | - S. Buglioni
- Regina Elena National Cancer Institute, Rome, Italy
| |
Collapse
|
36
|
Di Filippo F, Giacomini P, Rossi CR, Santinami M, Garinei R, Anzà M, Deraco M, Botti C, Perri P, Cavaliere F, Di Angelo P, Sofra C, Sperduti I, Pasqualoni R, Di Filippo S, Corrias F, Armenti A, Ferraresi V. Hyperthermic isolated perfusion with tumor necrosis factor-alpha and doxorubicin for the treatment of limb-threatening soft tissue sarcoma: the experience of the Italian Society of Integrated Locoregional Treatment in Oncology (SITILO). In Vivo 2009; 23:363-367. [PMID: 19414428] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
BACKGROUND Tumor necrosis factor-alpha (TNFalpha)-based hyperthermic isolated limb perfusion (HILP) is routinely carried out at most oncological institutions in the treatment of locally advanced soft tissue limb sarcoma (STS), employing high TNFalpha dosages. After a phase I-II study, the SITILO (Italian Society of Integrated Locoregional Therapies in Oncology) centers began to employ the lower dose of 1 mg of TNFalpha. The aim of this paper is to report on the results obtained in 75 patients with limb-threatening STS treated with a low TNFalpha dose and doxorubicin (Dx). PATIENTS AND METHODS HILP with TNFalpha (at a dosage of either <or=1 mg or >1 mg) and Dx was administered to 75 patients with limb-threatening STS: 37 males and 38 females; median age 50 years; tumor in the lower and upper limbs in 58 and 17 patients, respectively; primary and recurrent tumors in 45 and 30 patients, respectively. Most tumors (77%) were high grade. Tumor resection was carried out 6 to 8 weeks after HILP. RESULTS The grade of limb toxicity was mild to moderate in the vast majority of patients (76%). Grades IV and V were observed, but only when high muscle temperatures were recorded and high TNFalpha dosages were employed. Systemic toxicity was also mild to moderate and there were no postoperative deaths. Complete and partial tumor responses were 34% and 48%, respectively, with an overall response of 82% . Limb sparing surgery was carried out in 85.3% of patients. At a median follow-up of 28 months, 16 recurrences (21.3%) were recorded, with a 5-year locoregional disease-free survival of 63% . The 5-year disease-free survival and overall survival were 36.7% and 61.6%, respectively. CONCLUSION HILP with 1 mg of TNFalpha is an effective neoadjuvant therapy resulting in a high rate of limb sparing in limb-threatening STS, with acceptable local reactions and negligible systemic toxicity.
Collapse
Affiliation(s)
- F Di Filippo
- Department of Surgery, Regina Elena National Cancer Institute, Via Elio Chianesi, 53, 00144 Rome, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Di Filippo F, Giacomini P, Rossi CR, Santinami M, Anzà M, Garinei R, Perri P, Botti C, Di Angelo P, Sofra C, Pasqualoni R, Sperduti I, Cavaliere F, Di Filippo S, Corrias F, Armenti A, Ferraresi V, Ginebri A. Prognostic factors influencing tumor response, locoregional control and survival, in melanoma patients with multiple limb in-transit metastases treated with TNFalpha-based isolated limb perfusion. In Vivo 2009; 23:347-352. [PMID: 19414425] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
BACKGROUND In isolated limb perfusion (ILP) with tumor necrosis factor-alpha (TNFalpha) and interferon (IFN)-gamma, pioneered by Lienard and Lejenne in 1988, TNFalpha was empirically employed at a dosage (3-4 mg) ten times higher than the systemic maximum tolerable dose (MTD). We previously conducted a phase I/II study in 20 patients with in-transit melanoma metastases, using a combination of melphalan and TNFalpha at dosages ranging from 0.5 to 3.3 mg. The dose of 1 mg of TNFalpha was identified as optimal in terms of both efficacy and toxicity. The aim of the present study was to describe our experience with 113 stage IIIA/IIIAB melanoma patients treated with a TNFalpha-based ILP and identify prognostic factors for response, locoregional control and survival. PATIENTS AND METHODS Patients at stage IIIA-IIIAB (presence of in-transit metastases and/or regional node involvement) were considered eligible. The disease was bulky (>or=10 nodules<or=3 cm or fewer nodules with a diameter>3 cm) in 42.5% of the patients and unresectable in 33% . Forty patients were treated with a TNFalpha dosage of >1 mg and 73 with 1 mg. Patients with tumors in the upper and lower limbs were submitted to ILP via axillary and iliac vessels, respectively. TNFalpha was injected in the arterial line of an extracorporeal circuit at the pre-established dose, followed by melphalan (13 and 10 mg/l of limb volume for the upper and lower limbs, respectively) 30 minutes later. RESULTS Complete responses (CR) and partial responses (PR) were 63% and 24.5%, respectively, with an objective response (OR) of 87.5%. No change (NC) was observed in only 12.5% of the patients. Upon multivariate analysis, only bulky disease maintained its independent value for tumor response with an odds ratio of 4.07 and a p-value of 0.02. The 5-year locoregional disease-free survival was 42.7%. Upon multivariate analysis, the only prognostic factors were stage, age and bulky disease. The 5-year overall survival was 49%. Multivariate analysis showed that only sex, stage and CR maintained their independent values. CONCLUSION TNFalpha-based ILP was proven to be an effective treatment for melanoma patients with in-transit metastases. The TNFalpha dosage of 1 mg was as effective as 3-4 mg, with lower toxicity and cost. We propose that TNFalpha and melphalan-based ILP should be employed for bulky tumors or after failure of melphalan-based ILP.
Collapse
Affiliation(s)
- F Di Filippo
- Department of Surgery, Regina Elena National Cancer Institute, Via Elio Chianesi, 53, 00144 Rome, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Lopez M, Di Lauro L, Viola G, Foggi P, Conti F, Corsetti S, Sergi D, Botti C, Di Filippo F, Vici P. [Adjuvant chemotherapy in hormone-receptor positive HER2-negative early breast cancer]. Clin Ter 2009; 160:481-488. [PMID: 20198292] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
Adjuvant treatment in hormone-receptor positive, HER2-negative early breast cancer is controversial. Chemotherapy benefit in this subset of patients is generally small, and a wide variability exists among dif-ferent subgroups of patients, depending on various patient and tumor characteristics. To select subsets of patients who will really benefit from chemotherapy, one of the possible strategy is based on multigene expression analysis. This approach is providing deeper insights into the biological heterogeneity of breast cancer, allowing to further sub-divide hormone-receptor positive tumors into groups, with different clinical behavior and response to treatments. Among less expensive and better validated methods, high levels of Ki67, a routinely assessed immunohistochemical marker of cell proliferation, can suggest the use of chemotherapy in this subset of patients. Generally, regimen used should include a taxane. In fact, retrospective analyses of clinical trials suggest that anthracyclines may be less active in hormone-receptor positive HER2-negative patients, while several other trials and meta-analyses involving taxanes, showed a benefit in terms of risk of relapse and death reduction. Among taxanes, docetaxel should be preferred because of a better therapeutic index, and a higher activity in comparison to paclitaxel. At present, reliable and accurate evaluation of histopathological and immunohistochemical factors may allow the choice of omitting adjuvant chemotherapy in patients with low risk hormone receptor positive HER2-negative breast cancer. Uncertainty still exists about chemotherapy benefit for a substantial proportion of women of this subgroup. Nevertheless, the addition of taxanes, mainly docetaxel, to anthracyclines, seems to overcome the relative chemoresistance of hormone-receptor positive tumors, providing a benefit in disease free survival and overall survival.
Collapse
Affiliation(s)
- M Lopez
- Istituto Nazionale Tumori Regina Elena, Roma.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Vici P, Viola G, Botti C, Rossi S, Vitucci C, Corsetti S, Di Lauro L, Sergi D, Foggi P, Perri P, Tirelli C, Mottolese M, Fattoruso SIS, Lopez M. Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients. Clin Ter 2008; 159:449-452. [PMID: 19169607] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
Considering the clinical benefit of trastuzumab in advanced breast cancer, fi ve prospective adjuvant randomized trials have recently been completed and early results have been published. Two of them, (NSABP-B31 and NCCTG N9831), employed anthracycline-containing regimens with sequential paclitaxel, with or without trastuzumab. The third study, HERA trial, randomized patients after adjuvant chemotherapy into an observational arm, one or two years of trastuzumab. Results of these studies, after a median follow up of 2-3 years confirm a DFS and OS benefit for the experimental arms. The worst rate of cardiotoxicity, in terms of incidence of CHF, with the use of trastuzumab and anthracycline based regimens was 4.1% in the trastuzumab arm of the NSABP-B31 trial. Among the fi ve trastuzumab trials, two, BCIRG 006 and FinHer, employed docetaxel-based regimens. The innovative BCIRG 006 trial compared ACdocetaxel (T) with two trastuzumab-containing regimens, ACTH, and a non-anthracycline-containing regimens, TCH, with a clear advantage in DFS for both trastuzumab arms. Data from the second interim analysis indicate that, in the subgroup of patients without co-amplification of topoisomerase 2 (TOPO-2), the arm without trastuzumab (ACT) showed a DFS significantly poorer that in the other arms; moreover, if we consider the lower toxicity of TCH regimen in comparison with anthracycline-containing arms, the innovative statements offered by BCIRG 006 trial appear evident, and these findings opened an important question about the consolidated employment of anthracyclines in adjuvant setting.The FinHer trial was a small trial testing a short course of trastuzumab (9 weeks) concomitantly with a chemotherapy including docetaxel, and there was a significant advantage in DFS for the trastuzumab based arms, without relevant toxicity and without any cardiotoxicity. Although data from all trastuzumab adjuvant trials, and without particulary from BCIRG-006 and FinHer trials, appear very intriguing, further follow-up is required.
Collapse
MESH Headings
- Antibodies, Monoclonal/administration & dosage
- Antibodies, Monoclonal/therapeutic use
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents, Phytogenic/administration & dosage
- Antineoplastic Agents, Phytogenic/adverse effects
- Antineoplastic Agents, Phytogenic/therapeutic use
- Antineoplastic Combined Chemotherapy Protocols/administration & dosage
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Breast Neoplasms/drug therapy
- Breast Neoplasms/genetics
- Breast Neoplasms/pathology
- Carboplatin/administration & dosage
- Carboplatin/therapeutic use
- Chemotherapy, Adjuvant
- Clinical Trials, Phase III as Topic
- Cyclophosphamide/administration & dosage
- Cytarabine/administration & dosage
- Disease-Free Survival
- Docetaxel
- Epirubicin/administration & dosage
- Female
- Genes, erbB-2
- Heart Diseases/chemically induced
- Humans
- Multicenter Studies as Topic
- Neoplasm Proteins/antagonists & inhibitors
- Paclitaxel/administration & dosage
- Prospective Studies
- Randomized Controlled Trials as Topic
- Taxoids/administration & dosage
- Taxoids/adverse effects
- Taxoids/therapeutic use
- Topoisomerase II Inhibitors
- Trastuzumab
Collapse
Affiliation(s)
- P Vici
- Istituto Nazionale Tumori Regina Elena, Roma.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Vici P, Viola G, Rossi S, Botti C, Vitucci C, Sergi D, Ferranti FR, Saracca E, Di Lauro L, Corsetti S, Foggi P, Fattoruso SIS, Lopez M. Optimal sequence of anthracyclines and taxanes as adjuvant breast cancer treatment. Clin Ter 2008; 159:453-456. [PMID: 19169608] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
Results from randomized trials evaluating taxane versus non-taxane containing regimens in adjuvant breast cancer treatment indicate an advantage in DFS and OS for the taxane-arms, but the best schedule of administration, in combination with anthracyclines or in sequence, is still a debated issue, even if the sequential strategy appears to be less toxic. Up to now, the majority of clinical trials employed the "standard" sequence, with anthracycline-based combinations fi rst, followed by taxanes. Few small phase II trials evaluated the reverse sequence, with taxanes administered fi rst, most of them in metastatic or neoadjuvant setting, suggesting efficacy and lower toxicity. An important issue to be considered is the hypothesized differences in the ability of the drugs to induce cross-resistance to each other, as suggested by data of a preclinical study, and from clinical study with a cross-over design; results of these trials suggest that the best strategy would be to administer a taxane prior to an anthracycline, also according to the Norton and Simon hypothesis. Moreover, trials evaluating the best sequence of anthracyclines and taxanes in adjuvant breast cancer setting are of small sample size, and an adequately powered randomized phase III trial is needed before definitive conclusions are reached.
Collapse
Affiliation(s)
- P Vici
- Istituto Nazionale Tumori Regina Elena, Roma.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Fattoruso SIS, Rossi S, Vici P, Di Filippo F, Botti C, Di Lauro L, Foggi P, Saracca E, Ferranti FR, Visca P, Lopez M. [Optimal role of docetaxel in adjuvant chemotherapy for early stage HER2-negative breast cancer]. Clin Ter 2008; 159:443-447. [PMID: 19169606] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
The fundamental imperative of adjuvant treatment of early breast cancer is to improve long-term survival and minimize toxicity. The inclusion of docetaxel in adjuvant chemotherapy regimens has improved patient survival in comparison to anthracycline-containing regimens, even if the incidence of acute side effects has increased in some studies. However, late or persistent toxic effects are becoming more important due to an increasing proportion of patients remaining disease free after treatment for early breast cancer. Several studies have recently reported that docetaxel-containing regimens without anthracyclines are equally active, and have no apparent cardiotoxicity. At present, docetaxel-based combinations represent an appropriate choice in the adjuvant treatment of HER2-negative breast cancer, and several studies are ongoing aiming at a better evaluation of the efficacy of this agent in order to optimize its role.
Collapse
|
42
|
Fattoruso SIS, Rossi S, Di Lauro L, Botti C, Vici P, Lopez M. [Development of docetaxel in the adjuvant chemotherapy of breast cancer]. Clin Ter 2008; 159:369-376. [PMID: 18998039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
The development of taxanes in cancer chemotherapy required several decades of research mainly because of the difficulty related to supply and formulation of paclitaxel. Lesser difficulty was encountered in the development of docetaxel, which initially took place in breast cancer. In this disease, docetaxel showed a significant activity, probably superior to that of paclitaxel. In the first-generation studies in patients with early breast cancer, comparing anthracycline-based regimens with regimens containing anthracyclines and taxanes, docetaxel significantly improved survival independently from schedule, either sequential or concurrent. The aim of current second-generation studies, comparing taxanes in all study arms, is to answer several questions, including the best administration schedule and the best taxane to be used. Currently, the use of docetaxel in the adjuvant chemotherapy of breast cancer represents one of the most important achievements in the treatment of this disease. However, since further improvement in therapeutic results are needed, it is likely that in the future docetaxel will be used in combination with molecular targeted agents.
Collapse
|
43
|
Cobellis G, Silvestroni A, Lillo S, Sica G, Botti C, Maione C, Schiavone V, Rocco S, Brando G, Sica V. Long-term effects of repeated autologous transplantation of bone marrow cells in patients affected by peripheral arterial disease. Bone Marrow Transplant 2008; 42:667-72. [DOI: 10.1038/bmt.2008.228] [Citation(s) in RCA: 58] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
44
|
Bria E, Visca P, Novelli F, Casini B, Diodoro MG, Perrone-Donnorso R, Botti C, Sperduti I, Facciolo F, Milella M, Cecere FL, Cognetti F, Mottolese M. Nuclear and cytoplasmic cellular distribution of survivin as survival predictor in resected non-small-cell lung cancer. European Journal of Surgical Oncology (EJSO) 2008; 34:593-8. [PMID: 17693049 DOI: 10.1016/j.ejso.2007.06.002] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2007] [Accepted: 06/11/2007] [Indexed: 11/17/2022]
Abstract
AIM Survivin is a member of the inhibitors of apoptosis (IAP) gene family that acts through pathways different from those involving the bcl-2 family. Largely undetectable in normal adult tissues, survivin is deregulated in most human cancers including non-small-cell lung cancer (NSCLC) and may represent a tumor marker with prognostic and therapeutic implications. Aim of our study was to determine the prognostic role of survivin as an apoptosis-related biomarker in a series of resected NSCLC patients. METHODS A retrospective series of resected NSCLC patients were retrieved from the files of the Regina Elena National Cancer Institute. Survivin was detected by immunohistochemistry (IHC) using a polyclonal antibody. Survivin displayed two kinds of immunoreactivity: (i) a diffuse cytoplasmic staining and (ii) a distinct nuclear staining. A score-scale to distinguish positive (score 1-2) vs. negative (score 0) pattern was applied. Clinical and biological (nuclear and cytoplasmic survivin staining) covariables were screened for a prognostic relationship with overall survival (OS) and disease-free survival (DFS) into the univariate and multivariate analyses. RESULTS Data referring to 116 NSCLC patients who underwent surgery for stage I-IIIA NSCLC were collected. Multivariate analyses identified tumor size, nodal status and nuclear, but not cytoplasmic, expression of survivin as significant independent predictors of OS, with a hazard ratio of 2.40 (95% CI 1.44, 3.99, p=0.001), 2.03 (95% CI 1.26, 3.26, p=0.003) and 1.83 (95% CI 1.01, 3.30, p=0.044), respectively. Median OS for nuclear survivin positive (score 1-2) and negative (score 0) patients were 23 months (95% CI 15, 31) and 36 months (95% CI 1, 76), respectively (p=0.01); five-year survival for score 1-2 and score 0 patients were 20% and 44.5%, respectively. Conversely, no significant impact on survival is found when patients are stratified according to cytoplasmic survivin expression. CONCLUSIONS Data presented herein open the issue that prognosis of stage I-IIIA NSCLC can be linked to the cellular pattern of distribution of survivin.
Collapse
Affiliation(s)
- E Bria
- Medical Oncology, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Conti F, Carpano S, Sergi D, Di Lauro L, Amodio A, Vici P, Abbate MI, Ferranti FR, Viola G, Botti C, Foggi P, Sperduti I, Lopez M. [High-dose CEF (cyclophosphamide, epirubicin, fluorouracil) as primary chemotherapy in locally advanced breast cancer: long-term results]. Clin Ter 2007; 158:331-341. [PMID: 17953285] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
PURPOSE To determine wether primary CEF is effective in locally advanced breast cancer, as measured by response, local recurrences, disease free survival (DFS) and overall survival (OS). MATERIAL AND METHODS From 1990 to 1998, 62 patients with stage III disease were enrolled into a prospective study at Regina Elena Institute for Cancer Research, Rome. Inflammatory breast cancer (IBC) was included. Patients received three 21 days cycles of chemotherapy that consisted in epirubicin 50 mg/m2, cyclophosphamide 400 mg/m2, and fluorouracil 500 mg/m2 i.v. on days 1 and 8. G-CSF (300 microg) was given subcutaneously every other day from day 5 to day 17. After primary chemotherapy, whenever possible, mastectomy or conservative surgery was performed. Subsequently responding patients received the same regimen, while non responders were given a non cross resistant chemotherapy. In case of conservative surgery or initial T4 tumor radiation therapy was performed at the end of adjuvant chemotherapy. ER positive patients received tamoxifen 20 mg/d for five years. RESULTS Seven IIIA patients had a median OS of 43 months (C.I. 95%, 31-55) and DFS of 42 months (C.I. 95%, 16-68), while 15 IBC patients had a median OS of 52 months (C.I. 95%, 52-79) and DFS of 27 months (C.I. 95%, 14-39). Forty IIIB non inflammatory breast cancer patients had a median DFS of 87 months (C.I. 95%, 1-175); median OS was not reached. Ten-year OS was 28.6% for stage IIIA, 50.6% for stage IIIB and 36% for IBC. CONCLUSION Primary CEF appear to be an effective treatment. In our study we obtained a good local control and interesting long term data of disease free and overall survival.
Collapse
Affiliation(s)
- F Conti
- Divisione di Oncologia Medica B, Istituto Nazionale Tumori Regina Elena, Roma, Italia
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Minutilli E, Giannarelli D, Anzà M, Garinei R, Perri P, Botti C, Piarulli L, Bruno P, Rea S, Visca R, Mottolese M, Di Filippo S, Di Filippo F. Sentinel node biopsy in cutaneous melanoma: correlations between melanoma prognostic factors and sentinel node status. J Exp Clin Cancer Res 2007; 26:71-6. [PMID: 17550134] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/15/2023]
Abstract
This study aims to correlate the most important prognostic factors of primary melanoma with sentinel node (SN) positive for metastases. We have enrolled 84 patients subjected to sentinel node biopsies for cutaneous melanomas of Breslow's thickness > or = 0.75 mm by using an intra-operative gamma probe after lymphoscintigraphy, without blue dye support. SN metastases were reported in 27% of cases (14% by histology and 13% by immunohistochemistry). By chi-square test Breslow's thickness > 2mm (p= 0.004), IV and V Clark's level (p= 0.02), ulceration (p= 0.05) and high mitotic rate (p= 0.05) were statistically significant (p < 0.05) with reference to SN positive for metastases, unlike the site of cutaneous melanoma, vertical growth phase, tumour infiltrating lymphocytes, regression and vascular invasion. Breslow's thickness remains the first prognostic factor to be considered for sentinel node biopsy in cutaneous melanoma, but other markers must be carefully estimated.
Collapse
Affiliation(s)
- E Minutilli
- Department of Surgery, Regina Elena National Cancer Institute, Rome, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Psaila A, Pozzi M, Barone Adesi L, Varanese A, Costantini M, Gullo P, Panimolle M, Pugliese P, Botti C, Di Filippo F, De Vita R. Nipple sparing mastectomy with immediate breast reconstruction: a short term analysis of our experience. J Exp Clin Cancer Res 2006; 25:309-12. [PMID: 17167969] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/13/2023]
Abstract
Breast cancer surgery has greatly changed over the past decades; nowadays skin-sparing mastectomy (SSM) and immediate reconstruction is considered a valid oncological option to achieve good aesthetic results. The success of SSM led to several studies aimed to investigate NAC involvement whose removal increases the patient's sense of mutilation. In this study the Authors investigate the incidence of recurrences in nipple sparing mastectomy (NSM) comparing it with the other techniques to assess the actual risk of tumor involvement of the NAC; besides, they analyse the patients' satisfaction and the NSM impact on quality of life through the utilization of a questionnaire. Clinical complications, aesthetic as well as oncological and psychological results have been analysed. They conclude that in selected cases NSM can be performed without additional risks because the incidence of recurrence after NSM is similar to that of radical mastectomy. Moreover, the aesthetic and psychological outcome are considered positive by the patients.
Collapse
Affiliation(s)
- A Psaila
- Department of Plastic and Reconstructive Surgery, Department of General Surgery, "Regina Elena" Cancer Institute, Rome, Italy
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
de Nigris F, Botti C, Rossiello R, Crimi E, Sica V, Napoli C. Cooperation between Myc and YY1 provides novel silencing transcriptional targets of alpha3beta1-integrin in tumour cells. Oncogene 2006; 26:382-94. [PMID: 16878156 DOI: 10.1038/sj.onc.1209804] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
We show that human osteosarcoma cells (Saos-2) have downregulation of alpha3beta1-integrin compared to normal bone cells; this was further described in human osteosarcomas and in a primary murine sarcoma. The alpha3 gene was silenced in Saos-2 cells causing a low expression of alpha3beta1-integrin and reduction in collagen attachment with increasing migratory capacity. Chromatin immunoprecipitation assay performed on alpha3 promoter established that Myc and Yin Yang protein (YY1) cooperate in tandem to downregulate the alpha3 gene. This silencing mechanism involves the binding of Myc and YY1 to DNA and formation of complexes among Myc/Max, YY1, CREB-binding protein and deacetylation activity. The promoter containing deletions of E-boxes or YY1 cassettes failed to downregulate the transcription of a reporter gene as well as the inhibition of deacetylation activity. Overexpression of both Myc and YY1 was necessary to determine the alpha3-integrin promoter downregulation in normal osteoblasts. This downregulation of alpha3beta1-integrin can contribute to the acquisition of a more aggressive phenotype. YY1 regulated negatively the Myc activity through a direct interaction with the Myc/Max and deacetylase complexes. This represents a novel silencing mechanism with broad implications in the transcription machinery of tumours.
Collapse
Affiliation(s)
- F de Nigris
- Department of General Pathology, Division of Clinical Pathology, 1st School of Medicine, II University of Naples, Naples, Italy
| | | | | | | | | | | |
Collapse
|
49
|
Pisani F, Romano A, Anticoli Borza P, Marino M, Micheli A, Botti C, Petti MC. Diffuse large B-cell lymphoma involving the breast. A report of four cases. J Exp Clin Cancer Res 2006; 25:277-81. [PMID: 16918141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/11/2023]
Abstract
Non-Hodgkin lymphoma of the breast is an uncommon form of lymphoma occurring either primary disease (PBL) or part of systemic involvement. We report the clinical outcome of 4 consecutive cases with CD20+ diffuse large B-cell lymphoma (DLBCL) of the breast, in the attempt to further clarify the management of this disease. The median age was 53 years (39-61), stages were IIE (n=2), IIIE (n=1), and IV (n=1); IPI scores were 0 (n=2), 2 (n=2). Two cases were PBL, and 2 were secondary involvement of the breast. Two stage IIE patients received MACOP-B, radiation therapy was given to one of them and both achieved CR. The stage IIIE patient treated with MACOP-B plus Rituximab was in PR at the beginning of the Rituximab and achieved CR at the end of the treatment. The 61-year-old stage IV patient and bilateral involvement received P-VNBEC as first line treatment, achieving PR; she was then treated with 4 cycles of MACOP-B plus Rituximab obtaining CR. After a median follow-up of 40 months (31-50) all patients are alive and in CR. No CNS prophylaxis was given and no incidence of CNS relapse was observed. In our experience DLBCL of the breast shows chemosensitivity to MA-COP-B regimen but the intensification with Rituximab seems to be effective especially in the advanced stages. Further and comparative studies are required to confirm the validity of our results.
Collapse
Affiliation(s)
- F Pisani
- Department of Hematology, Regina Elena Cancer Institute, Rome, Italy.
| | | | | | | | | | | | | |
Collapse
|
50
|
Di Filippo F, Patrizi V, Cavaliere F, Garinei R, Anzà M, Perri P, Botti C, Di Filippo S, Vespa A. [Doxorubicin in antiblastic hyperthermic perfusion in the treatment of advanced soft-tissue sarcoma of the limbs]. Suppl Tumori 2005; 4:S126-7. [PMID: 16437946] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/06/2023]
Abstract
Different antineoplastic drugs have been associated to hyperthermia in the treatment of advanced soft tissue limb sarcoma with a good results in terms of conservative surgery (77%-97%), locoregional control (77%-87%) and overall survival (72%). Two different studies were performed: the first was carried out to analyze the doxorubicin-TNFalpha-hyperthermia association (three different trials) in terms of toxicity and efficacy of the treatment (tumor response, locoregional control, disease free and overall survival). The results showed that the trimodality association (doxorubicin TNFalpha and hyperthermia) is the best regimen able to obtain a 77% of objective response and 77% of limb sparing in patients candidate to amputation but may result in high local toxicity if high temperatures (>41.5 degrees C) were maintained during perfusion. The second study describes the employment of liposomal doxorubicin in hyperthermic antiblastic perfusion (HAP) in terms of tumor response, conservative surgery and toxicity; the maximum tolerable dose (MTD) of doxorubicin was 16 mg/l of perfused limb volume at the temperature of 41.5 degrees C; the conservative surgery was possible in 91% of the cases and mild (grade I and II) toxicity was observed in the perfused limb with high temperature (>41.5 degrees C).
Collapse
|